Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDrax Regulatory News (DRX)

Share Price Information for Drax (DRX)

Share Price is delayed by 15 minutes
Get Live Data
756.00    -4.50 (-0.59%)
Bid:
754.50
Ask:
755.50
Spread: 1.00 (0.133%)
Market Cap: £2.54b
DRX Live PriceLast checked at - London Stock Exchange

Intraday Drax Share Chart

2022 Performance Awards - EPS Condition

19 Apr 2022 12:00

RNS Number : 5995I
Drax Group PLC
19 April 2022
 

19 April 2022

Drax Group plc

("Drax" or the "Group"; Symbol:DRX)

 

2022 Performance Awards - EPS Condition

At the time of publishing the annual report for the financial year ended 31 December 2021, Drax advised it would be separately determining, and thereafter releasing details of, the Cumulative Adjusted Earnings per Share performance condition which applies to grants made to PDMRs and other employees in the 2022 financial year.

The vesting of awards granted are subject to satisfying two performance criteria over the financial years 2022, 2023 and 2024. 50% of the awards will be measured based on Relative Total Shareholder Return relative to the FTSE-350, and the remaining 50% will be measured based on Cumulative Adjusted Earnings per Share.

Following a meeting of the Remuneration Committee, the proposed Cumulative Adjusted EPS target for 2022 has been agreed. The EPS target was set after considering the company's internal forecasts, market expectations and sector peers.

 

 

Threshold

Target

Maximum

239.5p

266.1p

292.7p

 

 

BASIS OF VESTING

Performance

Target

% of Award Vesting(of EPS performance condition)

Below threshold

0%

Threshold

239.5p

25%

Maximum

292.7p

100%

 

Vesting between the threshold and maximum will be on a straight-line basis.

The EPS target is 'Adjusted EPS', derived from Adjusted Results as reported in the Company's audited financial statements. Instances where such adjustments might apply include acquisition and restructuring costs, asset obsolescence charges and certain remeasurements on derivative contracts.

There may arise circumstances during the performance period where adjustment or discretion is applied by the Remuneration Committee by reference to exceptional items and the Remuneration Policy. The application of such adjustments would be considered during and upon completion of the performance cycle. In making their assessment, the Remuneration Committee will take into account appropriate advice (for example from our auditors, Remuneration Committee advisers or the Audit Committee) and also give due consideration to the shareholder experience. The Remuneration Committee would also take into account exceptional and unforeseen circumstances, including wider considerations such as the prevailing market environment, in assessing the appropriate level of vesting judged against the performance of the Company and management at the end of the performance period.

Total Shareholder Return relative to the FTSE-350 will be measured over the three-year period (2022-2024) consistent with the approach previously approved by shareholders.

The Remuneration Committee of Drax considers that attaining outturn at the top end of the range would represent strong performance considering the uncertain economic circumstances and the challenges to the broader economy. 

 

Ends

 

Enquiries:

Drax Investor Relations: Mark Strafford

mark.strafford@drax.com 

+44 (0) 7730 763 949

Brett Gladden, Group Company Secretarybrett.gladden@drax.com+44 (0)7936 362586

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFEFSUEESEEL
Date   Source Headline
20th May 20255:28 pmRNSTransaction in Own Shares
20th May 20254:49 pmRNSCancellation of Auction Procedure
20th May 20254:39 pmRNSOffer Update
19th May 20255:37 pmRNSTransaction in Own Shares
16th May 20256:20 pmRNSTransaction in Own Shares
15th May 20255:21 pmRNSTransaction in Own Shares
15th May 202512:06 pmRNSHolding(s) in Company
14th May 20255:30 pmRNSTransaction in Own Shares
13th May 20255:34 pmRNSTransaction in Own Shares
12th May 20255:30 pmRNSTransaction in Own Shares
12th May 20257:00 amRNSTransaction in Own Shares
8th May 20255:40 pmRNSTransaction in Own Shares
7th May 20255:40 pmRNSTransaction in Own Shares
6th May 20255:38 pmRNSTransaction in Own Shares
2nd May 20255:26 pmRNSTransaction in Own Shares
1st May 20255:36 pmRNSTransaction in Own Shares
1st May 20253:21 pmRNSTotal Voting Rights
1st May 20252:49 pmRNSNotice of change to director details
1st May 202512:40 pmRNSResult of AGM
1st May 20257:00 amRNSTrading Update
30th Apr 20255:57 pmRNSTransaction in Own Shares
29th Apr 20255:57 pmRNSTransaction in Own Shares
29th Apr 202511:42 amRNSRule 2.10 - Schroder & Co Ltd
28th Apr 20256:11 pmRNSTransaction in Own Shares
25th Apr 20255:25 pmRNSTransaction in Own Shares
24th Apr 20256:03 pmRNSTransaction in Own Shares
23rd Apr 20255:34 pmRNSTransaction in Own Shares
23rd Apr 20252:54 pmRNSNotice of change of AGM venue
22nd Apr 20255:37 pmRNSTransaction in Own Shares
17th Apr 20255:41 pmRNSTransaction in Own Shares
16th Apr 20256:01 pmRNSTransaction in Own Shares
15th Apr 20255:36 pmRNSTransaction in Own Shares
15th Apr 20254:40 pmRNSDirector/PDMR Shareholding
11th Apr 20255:45 pmRNSTransaction in Own Shares
10th Apr 20258:45 amRNSAdditional Listing
9th Apr 20255:27 pmRNSTransaction in Own Shares
8th Apr 20255:55 pmRNSTransaction in Own Shares
7th Apr 20255:39 pmRNSTransaction in Own Shares
4th Apr 20256:00 pmRNSTransaction in Own Shares
3rd Apr 20256:08 pmRNSTransaction in Own Shares
2nd Apr 20255:34 pmRNSTransaction in Own Shares
1st Apr 20255:36 pmRNSTransaction in Own Shares
1st Apr 20253:42 pmRNSTotal Voting Rights
1st Apr 202510:18 amRNSBlock listing Interim Review
1st Apr 202510:17 amRNSBlock listing Interim Review
1st Apr 202510:16 amRNSBlock listing Interim Review
1st Apr 202510:14 amRNSBlock listing Interim Review
31st Mar 20255:35 pmRNSTransaction in Own Shares
28th Mar 20256:08 pmRNSTransaction in Own Shares
28th Mar 20258:00 amRNSMailing of Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.